Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM: Investigational Therapeutics for Ebola Virus Disease
NCT03719586Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 3 trial of remdesivir, ansuvimab, REGN-EB3 in Ebola virus disease (EVD), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2018; status: completed.
02
Drugs
remdesiviransuvimabREGN-EB3
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03719586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719586.